Stellantis N.V. Common Shares vs 10X Genomics Inc — how do they compare? Stellantis N.V. Common Shares trades at $4.28 (market cap $16.51B), while 10X Genomics Inc trades at $72.38 (market cap $9.35B). The key difference: Stellantis N.V. Common Shares is the larger of the two by market cap, and 10X Genomics Inc is trading nearer its 52-week high, Stellantis N.V. Common Shares nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Stellantis N.V. Common Shares for 0 Days and 10X Genomics Inc for 91 Days on average.
| STLA | TXG | |
|---|---|---|
Market Cap | $16.51B | $9.35B |
Volume | 28,274,156 | 4,039,449 |
Sector | Consumer Cyclical | Health |
52-Week High | $12.12 | $97.74 |
52-Week Low | $4.27 | $11.83 |
Typical Hold Time | 0 Days | 91 Days |
Enterprise Value | $36.19B | $8.88B |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
TXG trades at $73.10, down 2.78% on the day, with a bearish technical signal and neutral oscillators. The company reported revenue of $642.82M in 2025 but a net loss of $43.54M, though recent quarters show earnings beats. Analyst consensus is mixed with a $83.30 price target. Positive news includes Atera shipments and a patent victory, but profitability remains a challenge.
The outlook hinges on Atera's commercial success driving future revenue growth and margin improvement. Risks include persistent losses, competitive pressures, and execution delays. Upside potential exists if new platforms gain traction, but investors should weigh high valuation multiples against ongoing unprofitability.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Stellantis N.V. is a multinational automaker formed from the 2021 merger of Fiat Chrysler Automobiles and PSA Group, manufacturing vehicles under brands including Jeep, Ram, Chrysler, Dodge, Fiat, Peugeot, and Citroën.
Read more on STLA →10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →